問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Recruiting

List

265Cases

2020-01-06 - 2026-09-05

Phase III

Active
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    Selpercatinib (LY3527723)

Participate Sites
14Sites

Recruiting14Sites

2023-07-31 - 2026-05-27

Phase II

Completed
Master Protocol Title: A Master Protocol for Randomized, Controlled, Phase 2 Clinical Trials of Multiple Interventions for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis ISA Title: A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, 52 Week Study to Evaluate the Efficacy and Safety of LY3454738 in the Treatment of Adult Patients with Moderate-to-Severe Atopic Dermatitis

  • Condition/Disease

    f Adults with Moderate-to-Severe Atopic Dermatitis

  • Test Drug

    N/A

Participate Sites
8Sites

Recruiting8Sites

2024-04-01 - 2028-12-31

Phase III

Active
Global Study to Investigate Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease

  • Condition/Disease

    Alzheimer’s Disease

  • Test Drug

    injection

Participate Sites
11Sites

Recruiting11Sites

2024-02-01 - 2029-12-31

Phase III

Completed
Assessment of safety and efficacy of subcutaneous remternetug in early symptomatic Alzheimer’s disease

  • Condition/Disease

    Alzheimer’s disease

  • Test Drug

    injection

Participate Sites
7Sites

Recruiting7Sites

2025-01-01 - 2031-12-31

Phase III

Active
A Study of Remternetug Versus Placebo in Early Alzheimer’s Disease Participants at Risk for Cognitive and Functional Decline

  • Condition/Disease

    Early Alzheimer’s Disease

  • Test Drug

    injection

Participate Sites
12Sites

Recruiting12Sites

2022-10-01 - 2027-12-31

Phase III

Active
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity

  • Condition/Disease

    Overweight

  • Test Drug

    Tirzepatide（LY3298176）

Participate Sites
11Sites

Not yet recruiting2Sites

Recruiting9Sites

2021-05-03 - 2034-02-28

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting12Sites

2023-06-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
19Sites

Recruiting19Sites

2021-11-01 - 2026-02-28

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2022-04-01 - 2025-09-30

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting2Sites

Recruiting5Sites

1 13 14 15 16 17 27
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB